Table 3.
Summary of main in vitro and in vivo synergistic effects of terpenoids and other compounds in combination with chemotherapeutic compounds against CRC.
| References | Tested molecule | In combination with | Experimental model | Main result | Proposed mechanism |
|---|---|---|---|---|---|
| Carnesecchi et al., 2004; Vieira et al., 2011 | Geraniol | 5-FU | Caco-2 cell line | Synergistic: 20% reduction in cell survival | Down-regulation of Bcl-2 |
| Carnesecchi et al., 2004 | Geraniol | 5-FU | Mice xenograft (TC118) | Synergistic: 80% reduction in tumor size | Unknown |
| Serova et al., 2006 | Irofulven | Oxaliplatin | HT-29 cell line | Synergistic: reduced cell survival | Unknown |
| Britten et al., 1999 | Irofulven | Irinotecan | Mice xenograft (HT-29) | Synergistic: tumor size reduction | Unknown |
| Liu et al., 2011 | Artesunate | Oxaliplatin | HCT116 cell line | Synergistic: 50% cell killing | ROS induction |
| Liu et al., 2014 | Triptolide | Oxaliplatin | SW480 cell line | Synergistic: 62% cell killing | Apoptosis induction, blocking of β-catenin translocation to nucleus |
| Liu et al., 2014 | Triptolide | Oxaliplatin | Mice xenograft (SW480) | Synergistic: 60% tumor growth reduction | Unknown |
| Koh et al., 2012; Prasad et al., 2012 | Ursolic acid | Radiotherapy | CT26 and HCT116 cell lines | Synergistic: 55% cell killing | Apoptosis induction, caspase 3 activation, ROS increase, GSH, NF-kB and Bcl-2 reductions |
| Wang et al., 2015 | Ginsenolides | 5-FU | Mice xenograft (HCT116) | Synergistic: reduced tumor size | G1 arrest |
| Kim et al., 2009 | Ginsenolides | Docetaxel | HCT116 cell line | Synergistic: increased cell death | NF-kB inhibiton, Bcl-2 repression |
| Zhu et al., 2010 | Calastrol | TRAIL | SW620 cell line | Synergistic: increased cell killing | Apoptosis induction |
| Jung et al., 2007 | Betulinic acid | 5-FU, oxaliplatin, irinotecan | SNU-C5 cell line | Synergistic: increased cell killing, reduction in chemoresistance | Apoptosis induction (caspase 3) |
| Li et al., 2007 | Curcumin | Oxaliplatin | Lo-Vo cell line | Synergistic: growth inhibition | Unknown |
| Anitha et al., 2014 | Curcumin | 5-FU | HT-29 | Synergistic: increased cells killing | Apoptosis induction |
| Murakami et al., 2013 | Curcumin | Turmerones | CRC mouse model (dimethyl-hydrazine) | Synergistic: tumor size reduction | Apoptosis induction |
| Yue et al., 2016b | Curcumin | Bevacizumab | Mice xenograft (HT-29) | Synergistic: tumor size reduction | Apoptosis induction |
| Zhang et al., 2003; Lan et al., 2015 | Gossypol | 5-FU | Mice xenograft (HT-29) | Synergistic: tumor size reduction | Apoptosis induction, chemical sensitization |